Tags

Type your tag names separated by a space and hit enter

Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study.
J Urol. 2012 Aug; 188(2):526-31.JU

Abstract

PURPOSE

We investigated the effects of the administration of ubiquinol (a reduced form of coenzyme Q(10)) on semen parameters and seminal plasma antioxidant capacity in infertile men with idiopathic oligoasthenoteratozoospermia.

MATERIALS AND METHODS

A total of 228 men with unexplained infertility were randomly assigned 1:1 into 2 groups. Group 1 (114) received 200 mg ubiquinol daily by mouth for 26 weeks and group 2 (114) received a similar regimen of placebo. After completion of the 26-week treatment phase, all participants were followed for another 12-week off-drug period. Primary outcomes were improvement in sperm density, sperm motility and sperm strict morphology.

RESULTS

At the end of the 26-week treatment period mean ± SD sperm density in the ubiquinol and placebo groups was 28.7 ± 4.6 × 10(6)/ml and 16.8 ± 4.4 × 10(6)/ml (p = 0.005), sperm motility was 35.8% ± 2.7% and 25.4% ± 2.1% (p = 0.008), and sperm strict morphology was 17.6% ± 4.4% and 14.8% ± 4.1% (p = 0.01) of normal sperm, respectively. During the treatment period serum follicle-stimulating hormone levels decreased significantly (p = 0.02) and serum inhibin B concentrations increased significantly (p = 0.01). During the off-drug period semen parameters gradually returned to baseline values but the differences were still significant for sperm density (p = 0.03) and sperm motility (p = 0.03). The correlation coefficients analysis revealed a positive association between the duration of treatment with ubiquinol and sperm density (r = 0.74, p = 0.017), sperm motility (r = 0.66, p = 0.024) and sperm morphology (r = 0.57, p = 0.027).

CONCLUSIONS

Ubiquinol was significantly effective in men with unexplained oligoasthenoteratozoospermia for improving sperm density, sperm motility and sperm morphology.

Authors+Show Affiliations

Clinical Center for Urological Disease Diagnosis, Tehran, Iran. info@safarinejad.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22704112

Citation

Safarinejad, Mohammad Reza, et al. "Effects of the Reduced Form of Coenzyme Q10 (ubiquinol) On Semen Parameters in Men With Idiopathic Infertility: a Double-blind, Placebo Controlled, Randomized Study." The Journal of Urology, vol. 188, no. 2, 2012, pp. 526-31.
Safarinejad MR, Safarinejad S, Shafiei N, et al. Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. J Urol. 2012;188(2):526-31.
Safarinejad, M. R., Safarinejad, S., Shafiei, N., & Safarinejad, S. (2012). Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. The Journal of Urology, 188(2), 526-31. https://doi.org/10.1016/j.juro.2012.03.131
Safarinejad MR, et al. Effects of the Reduced Form of Coenzyme Q10 (ubiquinol) On Semen Parameters in Men With Idiopathic Infertility: a Double-blind, Placebo Controlled, Randomized Study. J Urol. 2012;188(2):526-31. PubMed PMID: 22704112.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen parameters in men with idiopathic infertility: a double-blind, placebo controlled, randomized study. AU - Safarinejad,Mohammad Reza, AU - Safarinejad,Shiva, AU - Shafiei,Nayyer, AU - Safarinejad,Saba, Y1 - 2012/06/15/ PY - 2011/11/19/received PY - 2012/6/19/entrez PY - 2012/6/19/pubmed PY - 2013/7/9/medline SP - 526 EP - 31 JF - The Journal of urology JO - J. Urol. VL - 188 IS - 2 N2 - PURPOSE: We investigated the effects of the administration of ubiquinol (a reduced form of coenzyme Q(10)) on semen parameters and seminal plasma antioxidant capacity in infertile men with idiopathic oligoasthenoteratozoospermia. MATERIALS AND METHODS: A total of 228 men with unexplained infertility were randomly assigned 1:1 into 2 groups. Group 1 (114) received 200 mg ubiquinol daily by mouth for 26 weeks and group 2 (114) received a similar regimen of placebo. After completion of the 26-week treatment phase, all participants were followed for another 12-week off-drug period. Primary outcomes were improvement in sperm density, sperm motility and sperm strict morphology. RESULTS: At the end of the 26-week treatment period mean ± SD sperm density in the ubiquinol and placebo groups was 28.7 ± 4.6 × 10(6)/ml and 16.8 ± 4.4 × 10(6)/ml (p = 0.005), sperm motility was 35.8% ± 2.7% and 25.4% ± 2.1% (p = 0.008), and sperm strict morphology was 17.6% ± 4.4% and 14.8% ± 4.1% (p = 0.01) of normal sperm, respectively. During the treatment period serum follicle-stimulating hormone levels decreased significantly (p = 0.02) and serum inhibin B concentrations increased significantly (p = 0.01). During the off-drug period semen parameters gradually returned to baseline values but the differences were still significant for sperm density (p = 0.03) and sperm motility (p = 0.03). The correlation coefficients analysis revealed a positive association between the duration of treatment with ubiquinol and sperm density (r = 0.74, p = 0.017), sperm motility (r = 0.66, p = 0.024) and sperm morphology (r = 0.57, p = 0.027). CONCLUSIONS: Ubiquinol was significantly effective in men with unexplained oligoasthenoteratozoospermia for improving sperm density, sperm motility and sperm morphology. SN - 1527-3792 UR - https://www.unboundmedicine.com/medline/citation/22704112/Effects_of_the_reduced_form_of_coenzyme_Q10__ubiquinol__on_semen_parameters_in_men_with_idiopathic_infertility:_a_double_blind_placebo_controlled_randomized_study_ L2 - https://www.jurology.com/doi/full/10.1016/j.juro.2012.03.131?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -